When Should Children of Alpha-1 Patients Be Tested?
Published: | Updated:
For healthy children without symptoms, medical guidelines recommend waiting until age 18 to test for Alpha-1 antitrypsin deficiency to protect their autonomy and future insurance options. However, if an infant or child shows signs of liver problems like jaundice, they should be tested immediately.
Key Takeaways
- • Healthy, asymptomatic children should wait until age 18 to undergo genetic testing for Alpha-1 to protect their future autonomy and insurance options.
- • Infants and children showing signs of liver problems, such as jaundice or elevated liver enzymes, must be tested immediately.
- • Testing the co-parent first is the recommended approach, as it helps determine the child's genetic risk without a pediatric blood draw.
- • A genetic diagnosis on a pediatric medical record can legally be used to deny the child life or disability insurance when they reach adulthood.
For infants showing signs of liver problems, testing for Alpha-1 antitrypsin deficiency (Alpha-1) should be done immediately [1]. However, for children who are healthy and have no symptoms, major medical guidelines recommend waiting until the child is 18 years old to pursue genetic testing [2][3]. Waiting preserves the child’s right to make their own informed choices about their genetic information and avoids potential impacts on their future [3][4].
Testing the Co-Parent First
Because Alpha-1 is an inherited condition, your child’s risk depends entirely on the genes they inherit from both biological parents [4][5]. If you have Alpha-1, your child will automatically inherit at least one Alpha-1 gene from you, making them a “carrier” at minimum [6].
Testing the other biological parent is often the most logical first step [4]. If the other parent does not carry any Alpha-1 mutations, your child will only be a carrier, which carries a much lower risk of severe disease [7][6]. This can provide tremendous peace of mind without ever having to draw blood from or test your child.
When Testing a Child is Medically Necessary
While Alpha-1 is often thought of as an adult lung condition, it can also cause liver disease in children. In some cases, the liver has trouble processing the abnormally shaped Alpha-1 proteins, causing them to build up and damage the liver [8].
Testing is crucial and should not be delayed if a baby or child shows symptoms of liver issues, such as:
- Neonatal cholestasis (reduced bile flow in newborns that can cause liver damage) [1]
- Jaundice (yellowing of the skin or eyes) [1]
- Unexplained elevated liver enzymes found during routine blood work [1]
- Unexplained liver enlargement or portal hypertension in toddlers or older children [9]
If your child is symptomatic, an early diagnosis allows their healthcare team to start specialized interdisciplinary care and actively monitor their liver health [1][9]. Keep in mind that while a preliminary Alpha-1 screening can be minimally invasive, a symptomatic child will need traditional venous blood draws to thoroughly check their liver function [1].
Why Guidelines Recommend Waiting for Healthy Children
For children who do not have symptoms, organizations like the American Academy of Pediatrics (AAP) and the American College of Medical Genetics and Genomics (ACMG) strongly advise against predictive genetic testing [2][10]. Because the lung complications of Alpha-1 typically do not appear until between ages 20 and 50 [11][12], there is no immediate medical treatment or intervention prescribed for healthy children with Alpha-1 [13].
Instead of testing, the primary medical advice for managing the risk in asymptomatic children focuses on preventative health behaviors that benefit all children, primarily avoiding exposure to secondhand tobacco smoke and vaping, and maintaining good indoor air quality [13][12].
Waiting until age 18 to test asymptomatic children is recommended for several reasons:
- Preserving Autonomy: It allows the child to grow up and decide for themselves if they want to know their genetic status [2][3].
- Protecting Mental Health: Knowing they have a genetic risk for a late-onset disease can cause unnecessary anxiety, fear, and psychological burden during childhood [14][2].
- Safeguarding Future Insurance: While the Genetic Information Nondiscrimination Act (GINA) protects against discrimination in health insurance and employment, it does not apply to life insurance, disability insurance, or long-term care insurance [15][16]. Having a genetic diagnosis on their pediatric medical record could legally be used by companies to deny them life insurance coverage as adults [15][17].
How Testing is Done
When it is time to screen for Alpha-1—whether testing the co-parent or an adult child—the initial process is much easier than it used to be. The diagnostic process can be done using non-invasive methods:
- Buccal (cheek) swabs: A small cotton swab is rubbed on the inside of the cheek to collect DNA. Note: This method only identifies your specific genetic mutations; it does not measure Alpha-1 protein levels in the blood [18].
- Finger pricks: A tiny needle pricks the finger to collect a few drops of dried blood on a specialized card. This method can check both your genetic mutations and your Alpha-1 protein levels [5].
Seeking Genetic Counseling
The decision of whether or not to test a child is deeply personal and can be highly stressful. The Alpha-1 Foundation and medical guidelines strongly recommend genetic counseling [4]. A genetic counselor can help you navigate the medical, emotional, and social impacts of testing, ensuring you have the support you need to make the best decision for your family [4].
Frequently Asked Questions
When should my child be tested for Alpha-1?
Why do doctors recommend waiting until my child is 18 to test for Alpha-1?
Should my partner be tested for Alpha-1 before we test our child?
What symptoms indicate my child needs immediate Alpha-1 testing?
How is genetic testing for Alpha-1 performed?
Questions for Your Doctor
- • How can we ensure my child's medical records reflect their family history of Alpha-1 without implying a formal diagnosis?
- • Are there any baseline liver function blood tests we should include in my child's annual pediatrician visits, even without genetic testing?
- • Can you connect us with a genetic counselor who has experience with Alpha-1 families to help us evaluate the co-parent's genetics?
- • If we choose not to test right now, what specific signs of liver distress should we be watching for as my child grows?
Questions for You
- • Am I considering testing to help my child medically, or am I seeking testing to relieve my own anxiety?
- • How might my child react emotionally if they learn they have a genetic risk for a disease that won't affect them for decades?
- • Has my child's other biological parent been tested yet, and what were their results?
- • Am I prepared for the possibility that testing my child now could complicate their ability to get life insurance as an adult?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
A Challenging Case of Severe Infantile Cholestasis in Alpha-1 Antitrypsin Deficiency.
Khan Z, Venkat VL, Soltys KA, et al.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2017; (20(2)):176-181 doi:10.1177/1093526616686259.
PMID: 28326955 - 2
Rethinking the "open future" argument against predictive genetic testing of children.
Garrett JR, Lantos JD, Biesecker LG, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(10)):2190-2198 doi:10.1038/s41436-019-0483-4.
PMID: 30894702 - 3
Expert Perspectives on the Management of Alpha 1-Antitrypsin Deficiency.
Conde B, Costa F, Gomes J, et al.
Acta medica portuguesa 2023; (36(1)):49-54 doi:10.20344/amp.18497.
PMID: 35848753 - 4
Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.
Foil KE
Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211015954 doi:10.1177/20406223211015954.
PMID: 34408833 - 5
Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.
Greulich T, Vogelmeier CF
Therapeutic advances in respiratory disease 2016; (10(1)):72-84 doi:10.1177/1753465815602162.
PMID: 26341117 - 6
Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.
Henao MP, Craig TJ
Expert review of respiratory medicine 2016; (10(12)):1281-1294 doi:10.1080/17476348.2016.1249851.
PMID: 27771979 - 7
Alpha1 antitrypsin deficiency due to an homozygous PI* Null Q0Cairo mutation: Early onset of pulmonary manifestations and variability of clinical expression.
Jouhadi Z, Odou MF, Zerimech F, et al.
Respiratory medicine case reports 2018; (24()):58-62 doi:10.1016/j.rmcr.2018.04.005.
PMID: 29977761 - 8
SERPINA1 and MAN1B1 polymorphisms are not linked to severe liver disease in a French cohort of alpha-1 antitrypsin deficiency children.
Joly P, Lachaux A, Ruiz M, et al.
Liver international : official journal of the International Association for the Study of the Liver 2017; (37(11)):1608-1611 doi:10.1111/liv.13586.
PMID: 28887821 - 9
Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.
Fromme M, Klebingat F, Ellis P, Strnad P
Hepatology communications 2025; (9(5)) doi:10.1097/HC9.0000000000000699.
PMID: 40227077 - 10
The psychological impact of genetic information on children: a systematic review.
Wakefield CE, Hanlon LV, Tucker KM, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2016; (18(8)):755-62 doi:10.1038/gim.2015.181.
PMID: 26741411 - 11
[Alpha-1-antitrypsin deficiency].
de Vos JD, Hillberg O, Perch M, et al.
Ugeskrift for laeger 2021; (183(30)).
PMID: 34356027 - 12
[Alpha-1 antitrypsin deficiency].
Dasí F
Medicina clinica 2023; (160(5)):203-205 doi:10.1016/j.medcli.2022.09.001.
PMID: 36253208 - 13
Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives.
Quinn M, Ellis P, Pye A, Turner AM
Therapeutics and clinical risk management 2020; (16()):1243-1255 doi:10.2147/TCRM.S234377.
PMID: 33364772 - 14
Spirituality, Illness Unpredictability, and Math Anxiety Effects on Negative Affect and Affect-Management Coping for Individuals Diagnosed with Alpha-1 Antitrypsin Deficiency.
Worthington AK, Parrott RL, Smith RA
Health communication 2018; (33(4)):363-371 doi:10.1080/10410236.2016.1266576.
PMID: 28059573 - 15
Prohibiting Genetic Discrimination to Promote Science, Health, and Fairness.
American journal of human genetics 2019; (104(1)):6-7 doi:10.1016/j.ajhg.2018.12.005.
PMID: 30609408 - 16
Beyond the Genetic Information Nondiscrimination Act: ethical and economic implications of the exclusion of disability, long-term care and life insurance.
Tenenbaum JD, Goodman KW
Personalized medicine 2017; (14(2)):153-157 doi:10.2217/pme-2016-0078.
PMID: 29754558 - 17
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges.
Dixon P, Horton RH, Newman WG, et al.
Health economics, policy, and law 2024; (19(4)):446-458 doi:10.1017/S1744133124000070.
PMID: 38752549 - 18
Genetic diagnosis of α1-antitrypsin deficiency using DNA from buccal swab and serum samples.
Belmonte I, Barrecheguren M, Esquinas C, et al.
Clinical chemistry and laboratory medicine 2017; (55(9)):1276-1283.
PMID: 28107169
This page provides general information about pediatric testing guidelines for Alpha-1 antitrypsin deficiency. It is not medical advice; please consult your pediatrician or a genetic counselor to determine the best testing approach for your family.
Stay up to date
Get notified when new research about Alpha-1-antitrypsin deficiency is published.
No spam. Unsubscribe anytime.